60759-10-6

• 常用中文名：4-(1,3-三唑-4-基)苯胺
• 常用英文名：CHEMBRDG-BB 4010333
• CAS号：60759-10-6
• 分子式：C₉H₈N₂S
• 分子量：176.23800
• 发布时间：2018-12-28 10:31:36
• 更新时间：2024-01-03 16:10:31

名称

• 中文名: 4-(1,3-三唑-4-基)苯胺
• 英文名: 4-(1,3-thiazol-4-yl)aniline
• 英文别名: 4-Thiazol-4-yl-anilin; 4-thiazol-4-yl-aniline

物化性质

• 密度: 1.262g/cm3
• 沸点: 347.414ºC at 760 mmHg
• 分子式: C₉H₈N₂S
• 分子量: 176.23800
• 闪点: 163.91ºC
• 精确质量: 176.04100
• PSA: 67.15000
• LogP: 2.97350
• 折射率: 1.66

安全

• 符号: GHS05, GHS06
• 信号词: Danger
• 危害声明: H301-H318
• 警示性声明: P280-P301 + P310-P305 + P351 + P338
• 危险品运输编码: UN 2811 6.1 / PGIII
• 海关编码: 2934100090

合成路线

3704-42-5 ~% 60759-10-6

文献：Ochiai et al. Yakugaku Zasshi, 1939 , vol. 59, p. 462,468; dtsch. Ref. S. 228, 233 Chem.Abstr., 1954 , p. 0 5449

53101-04-5 ~% 491577-82-3 60759-10-6

文献：SELEXAGEN THERAPEUTICS, INC.; VERNIER, Jean-Michel; MAY, John; O'CONNOR, Patrick; RIPKA, William; PINKERTON, Anthony; BOUNAUD, Pierre-Yves; HOPKINS, Stephanie Patent: WO2011/85128 A1, 2011 ; Location in patent: Page/Page column 55 ;

99-81-0 ~% 60759-10-6

文献：EPIZYME, INC.; CHESWORTH, Richard; KUNTZ, Kevin, Wayne; OLHAVA, Edward, James; PATANE, Michael, A. Patent: WO2012/82436 A2, 2012 ; WO 2012/082436 A2

99-81-0 ~% 491577-82-3 60759-10-6

文献：SELEXAGEN THERAPEUTICS, INC.; VERNIER, Jean-Michel; MAY, John; O'CONNOR, Patrick; RIPKA, William; PINKERTON, Anthony; BOUNAUD, Pierre-Yves; HOPKINS, Stephanie Patent: WO2011/85128 A1, 2011 ;

1826-12-6 ~% 60759-10-6

文献：Erlenmeyer et al. Helvetica Chimica Acta, 1947 , vol. 30, p. 2058,2061

115-08-2 2631-71-2 ~% 60759-10-6

文献：Kulkarni; Fernandez; Patel; Bellare; Deliwala Journal of pharmaceutical sciences, 1969 , vol. 58, # 7 p. 852 - 857

532-27-4 ~% 60759-10-6

文献：Erlenmeyer et al. Helvetica Chimica Acta, 1947 , vol. 30, p. 2058,2061

上下游产品

上游产品  7
3704-42-5 53101-04-5 99-81-0 1826-12-6
115-08-2 2631-71-2 532-27-4
下游产品  0

海关

海关编码	2934100090
中文概述	2934100090. 结构上含有一个非稠合噻唑环的化合物(不论是否氢化). 增值税率:17.0%. 退税率:9.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途
Summary	2934100090 other compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0%